Volume 3.08 | Mar 5

Cancer Stem Cell News 3.08 March 5, 2014
Cancer Stem Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Cancer Stem Cell News on Twitter
 
TOP STORY
Flavaglines Target Primitive Leukemia Cells and Enhance Anti-Leukemia Drug Activity
Scientists demonstrate that rocaglamide and silvestrol, closely related natural products from the flavagline class of compounds, are able to preferentially kill functionally defined leukemia stem cells while sparing normal stem and progenitor cells. [Leukemia] Abstract
Culture Human Glioma-Derived Tumorspheres with NeuroCult™ - View Publications
 
PUBLICATIONS (Ranked by impact factor of the journal)
Chemical Ablation of Tumor-Initiating Human Pluripotent Stem Cells
This protocol describes two efficient and robust ways to chemically eliminate the tumor-initiating human pluripotent stem cells from monolayer culture. [Nat Protoc] Abstract

DDB2 Suppresses Tumorigenicity by Limiting the Cancer Stem Cell Population in Ovarian Cancer
A novel role was identified for DNA damage binding protein 2 (DDB2) in the tumorigenesis of ovarian cancer cells and the prognosis of ovarian cancer patients. [Mol Cancer Res] Abstract

NAC, Tiron and Trolox Impair Survival of Cell Cultures Containing Glioblastoma Tumorigenic Initiating Cells by Inhibition of Cell Cycle Progression
Investigators aimed to determine the mechanisms involved in the response to antioxidants of a human cell culture containing glioblastoma tumorigenic initiating cells. [PLoS One] Full Article

The Culture of Cancer Cell Lines as Tumorspheres Does Not Systematically Result in Cancer Stem Cell Enrichment
Scientists attempted to generate tumorspheres from several murine and human cancer cell lines: B16-F10, HT-29, MCF-7 and MDA-MB-231 cells. Tumorspheres were obtained with variable efficiencies from all cell lines except from MDA-MB-231 cells. [PLoS One] Full Article

Prognostic Value of Stem Cell Quantification in Stage II Colon Cancer
Researchers aimed to evaluate the prognostic value of cancer stem cells in a highly homogeneous population of stage II colon cancer. One hundred stage II colon cancer patients treated by the same surgical team between 1977 and 2005 were retrospectively analyzed. [PLoS One] Full Article

Hypoxia Promotes Stem-Like Properties of Laryngeal Cancer Cell Lines by Increasing the CD133+ Stem Cell Fraction
Investigators cultured the two cell lines under hypoxia and normoxia and examined the influence of hypoxia on the expression of hypoxia-inducible factors and the cancer stem-like properties of these cells, including cell cycle distribution, expression of stem cell genes (OCT4, SOX2 and NANOG) and laryngeal cancer stem cell surface marker (CD133), proliferation, invasion, colony formation and sphere formation capacity. [Int J Oncol] Abstract

Genistein-Inhibited Cancer Stem Cell-Like Properties and Reduced Chemoresistance of Gastric Cancer
Scientists showed that low doses of genistein, extracted from Millettia nitida Benth var hirsutissima Z Wei, inhibit tumor cell self-renewal in two types of gastric cancer cells by colony formation assay and tumor sphere formation assay. [Int J Mol Sci] Abstract | Full Article

Proliferation Inhibition and Differentiation Induction of Hepatic Cancer Stem Cells by Knockdown of BC047440: A Potential Therapeutic Target of Stem Cell Treatment for Hepatocellular Carcinoma
The authors aimed to determine whether BC047440 is involved in maintaining hepatic cancer stem cells (HCSC) malignant behavior (including proliferation and differentiation). They demonstrated that BC047440 expression was markedly upregulated in HCSCs. [Oncol Rep] Abstract

Culture and Characterize Mouse Mammary Epithelial Progenitors with Serum-Free EpiCult-B (Mouse) Free Protocols
 
REVIEWS
CD133-Targeted Niche-Dependent Therapy in Cancer: A Multipronged Approach
The authors have demonstrated that the CD133+ cancer stem cells (CSCs) reside in complex vascular niches, where reciprocal signaling between the CD133+ CSCs and their microenvironment may govern niche morphogenesis and homeostasis. They discuss the multifaceted functional role of the CD133+ cells in the context of their niche, and the potential of targeting CD133 as a niche-dependent approach in effective therapy. [Am J Pathol] Abstract

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

Attend the 9th Annual World Stem Cells & Regenerative Medicine Congress in London!
 
INDUSTRY NEWS
Cellectar Announces Initiation of Phase II Imaging Trial with I-124-CLR1404 in Patients with Newly Diagnosed or Recurrent Glioblastoma
Cellectar Biosciences, Inc. announced enrollment of the first patient in its Phase II imaging trial of I-124-CLR1404 in patients with glioblastoma. [Cellectar Biosciences, Inc.] Press Release

Alchemia Announces the In-Licensing of FAK Inhibitors from Cancer Research Technology
Alchemia Limited has licensed two early stage anticancer drug candidates from Cancer Research Technology and will evaluate them in various cancer and cancer stem cell models. The preclinical Focal Adhesion Kinase inhibitors will be evaluated on their effect on the tumor environment and cancer stem cells that are essential for the growth, persistence and reoccurrence of cancer. [Alchemia Limited] Press Release

From our sponsor: Free human hematopoietic progenitors wallchart. Request your copy.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW Biology and Treatment of Metastatic Cancers
September 23-26, 2014
El Jadida, Morocco

Visit our events page to see a complete list of events in the cancer stem cell community.
 
JOB OPPORTUNITIES
NEW Director of GMP/GLP Quality Operations (University of Pennsylvania, Perelman School of Medicine)

NEW Scientific Communications & Publishing Coordinator (STEMCELL Technologies, Inc.)

Postdoctoral Scientist – Small Cell Lung Cancer Circulating Tumor Cell Derived Explant Tumor Models (Cancer Research UK Manchester Institute)

Faculty Position – Cancer Biology and Evolution (Moffitt Cancer Center & Research Institute)

Postdoctoral Researcher – Molecular Biology and Cancer Research (Washington State University)

Postdoctoral Position – Molecular Mechanisms of Cell Division (Memorial Sloan Kettering Cancer Center)

Postdoctoral Position – Stem Cell Signaling and Epigenetics (Fondazione Istituto Nazionale Genetica Molecolare)

Research Assistant – Stem Cell & Leukemia Epigenetic (King’s College London)

Postdoctoral Fellow – Morphogenetic Signaling Pathways in Development and Disease (University of Rochester Medical Center)

Postdoctoral Research Fellow (Brigham & Women’s Hospital and Harvard Medical School)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

Comments or Suggestions? Email Comments or suggestions? Submit your feedback here
Learn more about Cancer Stem Cell News: Archives | Events | Contact Us